Gadolinium Lawyers Canada

Canada Lawyers Investigating Claims on Behalf of Canadians Harmed by Gadolinium-Based Contrast Agents

March 9, 2007—Health Canada warned of the association between Gadolinium-based contrast agents and nephrogenic systemis fibrosis (NSF) and nephrogenic fibrosing dermopathy (NFD) in a letter to healthcare professionals.

Health Canada noted that the majority of NSF/NSD cases occurred after the patient was administered Omniscan, with additional instances following exposure to Magnevist and Optimark.

Warning Alerts Patients to Risk of Gadolinium-Based Contrast Agents

The following gadolinium-based contrast agents are included in the Health Canada warning:

  • Magnevist (gadopentetate dimeglumine)
  • Omniscan (gadodiamide)
  • OptiMARK (gadoversetamide)
  • MultiHance (gadobenate dimeglumine)
  • ProHance (gadoteridol)
  • Gadovist (gadobutrol)
  • Vasovist (gadofosveset trisodium)

FDA Warns of Risk Caused by Gadolinium-Based Contrast Agents

 

May 23, 2007—Gadolinium-based contrast agents now must carry a black box warning due to the risk of a potentially fatal disease.

Patients with kidney disease or chronic liver disease risk developing nephrogenic systemic fibrosis. This disease is characterized by the thickening of skin and connective tissues, inhibiting a person's ability to move. Nephrogenic systemic fibrosis can be fatal.

The FDA first warned medical providers of a link between gadolinium-based agents and nephrogenic systemic fibrosis in June 2006. The warning was updated in December 2006.

The agency stated it was aware of at least 128 reports of nephrogenic systemic fibrosis in patients who were administered a gadolinium-based contrast agent.

About Gadolinium Contrast Agents

Contrast agents commonly are used during medical imaging procedures to highlight specific parts of the body, making them easier to see.

Gadolinium is a metal ion administered to patients undergoing magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) to provide a clearer picture of organs and tissues.

Gadolinium Lawyers Canada

vioxx lawyers canada

Greg Monforton and Partners is investigating legal claims against on behalf of Canadians who developed nephrogenic systemic fibrosis after being administered a gadolinium-based contrast agent.

If you or a loved one has been harmed by a Gadolinium contrast agent, we encourage you to contact us. We will represent clients throughout Canada in lawsuits against the manufacturers of these contrast agents.

For free answers to your questions about Gadolinium contrast agents, please complete our online form.

Current Consumer Cases

Contact Us

Name
Phone
Email

About Our Lawyers

Greg Monforton and Partners has grown to a highly respected products liability law firm with offices conveniently located throughout Windsor and Essex County, together with affiliate relationships with law firms throughout Ontario, Canada and the United States.

We are committed to protecting the rights of individuals injured by dangerous pharmaceuticals. The firm never represents insurance companies or product manufacturers. We only help people.

Gadolinium News

FDA Orders Warnings on MRI Contrast Agents
 
The Wall Street Journal
May 23, 2007
FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI Imaging
 
FDA
May 23, 2007
FDA Orders Black Box Warning for Gadolinium-Based Contrast Agents
 
MedPageToday
May 23, 2007